恩华药业(002262.SZ)：子公司签署产品独家商业合作协议

Core Viewpoint - Enhua Pharmaceutical has entered into exclusive commercial cooperation agreements with Shandong Green Leaf Pharmaceutical and its subsidiary, allowing Enhua to promote and sell three long-acting antipsychotic injectable products in mainland China [1] Group 1: Agreement Details - Enhua's subsidiary, Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., will receive exclusive rights to promote and sell three products: Risperidone microspheres (Rui Ketuo®), Paliperidone palmitate injection (Rui Bailai®), and Paliperidone palmitate injection (Mei Bi Rui®) [1] - Enhua will make a one-time non-refundable payment of $20 million to Green Leaf Pharmaceutical and Green Leaf Jiaao as consideration for the rights and licenses granted under the agreement [1] - Enhua is expected to achieve a total sales revenue of no less than 2.7 billion RMB (including tax) for the cooperative products from 2026 to 2035 [1] Group 2: Financial Arrangements - Green Leaf Pharmaceutical and Green Leaf Jiaao will pay Enhua service fees based on the procurement and sales performance of the licensed products [1]